Research · 2026-06-03
Researchers Propose Cannabis-Style Dual-Track Regulatory Framework for Kratom
Source: Journal of Addiction Medicine
Why it matters
This narrative review provides a practical roadmap for how the U.S. could scientifically evaluate and regulate kratom, drawing lessons from cannabis regulation to avoid the policy pitfalls of both overly permissive and overly restrictive approaches.
The big picture
With millions of Americans using kratom and a patchwork of state regulations ranging from outright bans to consumer-protection frameworks, a coherent, evidence-based federal approach is urgently needed. Researchers from Baylor College of Medicine argue that treating all kratom products the same ignores a critical distinction: natural whole-leaf kratom and concentrated or semisynthetic derivatives like 7-hydroxymitragynine carry fundamentally different risk profiles.
Key findings
- A June 2026 narrative review in the Journal of Addiction Medicine proposes a "dual track" regulatory framework modeled on cannabis regulation
- Natural whole-leaf kratom and enriched or semisynthetic derivatives (such as 7-OH) should follow different evidence standards and regulatory pathways
- Research priorities identified include chemically defined preparations, validated analytical methods, and human pharmacokinetic/pharmacodynamic studies
- Abuse liability assessment and cognitive testing are flagged as essential research requirements before broader approval
- Coordinated federal support is called for to align product standardization, early-phase clinical trials, and comparative effectiveness evaluations
- Authors argue semisynthetic constituents like 7-OH should follow conventional pharmaceutical drug development pathways
What they say
"The regulatory framework for kratom should consider a dual track," the authors write, noting that kratom's possible therapeutic applications can be examined while safeguarding public health through differentiated oversight of natural and semisynthetic products.
Bottom line
A June 2026 Journal of Addiction Medicine narrative review proposes a dual-track regulatory framework for kratom, calling for natural leaf products and concentrated or semisynthetic derivatives to follow entirely different evidence standards and approval pathways.